AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Immuneering Corporation Class A Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG009QXJQV7
3.73▼ 0.08 (-2.10%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
3.81
Day's Range
3.59 – 3.78
52-Week Range
3.38 – 8.48
Volume
726.3K
Avg Volume
699.7K
Share Statistics
Shares Outstanding
Employees
53
Exchange
XNAS
Listed
2021-07-30
Share count as of July 31, 2026

Immuneering Corporation Class A Common Stock (IMRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Immuneering Corporation Class A Common Stock (IMRX)
What is Immuneering Corporation Class A Common Stock's Market Cap?
Immuneering Corporation Class A Common Stock's Market Cap is $241.3M, based on as-reported figures from SEC (XBRL) filings.
What is Immuneering Corporation Class A Common Stock's Enterprise Value?
Immuneering Corporation Class A Common Stock's Enterprise Value is $200.0M, based on as-reported figures from SEC (XBRL) filings.
What is Immuneering Corporation Class A Common Stock's EV / EBITDA?
Immuneering Corporation Class A Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Immuneering Corporation Class A Common Stock's Net Income (TTM)?
Immuneering Corporation Class A Common Stock's Net Income (TTM) is -$57.3M, based on as-reported figures from SEC (XBRL) filings.
What is Immuneering Corporation Class A Common Stock's EBITDA?
Immuneering Corporation Class A Common Stock's EBITDA is -$63.1M, based on as-reported figures from SEC (XBRL) filings.
What is Immuneering Corporation Class A Common Stock's Diluted EPS (TTM)?
Immuneering Corporation Class A Common Stock's Diluted EPS (TTM) is -0.89, based on as-reported figures from SEC (XBRL) filings.
What is Immuneering Corporation Class A Common Stock's Net Debt?
Immuneering Corporation Class A Common Stock's Net Debt is -$41.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · IMRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development—
General and administrative—
Amortization of intangible asset—
Total operating expenses—
Loss from operations—
Other income (expense)
Interest income—
Other income, net—
Net loss
Net loss per share attributable to common stockholders, basic (in dollars per share)—
Net loss per share attributable to common stockholders, diluted (in dollars per share)—